Abbott Introduces Next Generation Laboratory Automation Solution to Help Meet Increased Testing Demand

Tue Apr 16, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

ABBOTT PARK, Ill.,  April 16, 2013  /PRNewswire/ -- Abbott (NYSE: ABT) today
announced the global launch of the ACCELERATOR®a3600, a next generation
automation solution, to help laboratories address the need to process tests
faster while handling increased volume. Advances in technology and automation
within the lab have led to more timely results leading to improved patient care.
Automation systems include the various instruments, devices, and software
algorithms used in laboratories.

"As laboratories around the world face challenges due to staffing shortages,
budget constraints, and increased demands, advances in automation technology
such as Abbott's ACCELERATOR a3600 can help labs be more efficient and
productive," said  Brian Blaser, executive vice president, Diagnostics Products,
Abbott. "Labs using automation can achieve more than 40 percent greater
efficiency, helping them adapt to meet current and future demand, which is
particularly important as approximately 70 percent of medical decisions are
informed by diagnostic testing."  1,2

The ACCELERATOR  a3600 is a laboratory automation track system that can process
up to 3,600 samples per hour and handle multiple tube sizes and types
simultaneously. By automating routine, manual tasks, this system may help labs
reduce error and improve efficiency. Another advantage of the system is a
modular design that offers labs the ability to install up to 99 combined
analyzers and modules on a single system, which means that labs can address
their testing needs today while planning for the future.  

The ACCELERATOR  a3600 automation solution, developed with Abbott partner
Swiss-based Inpeco SA, is available worldwide pending country registration. To
learn more about the role diagnostics can play in increasing quality and
efficiency in labs, please click  here.

Intended Use

The ACCELERATOR  a3600 is a modular system designed to automate pre-analytical
and post-analytical processing, sample-handling, and processing in the
laboratory. The system consolidates multiple analytical instruments into a
unified workstation by employing a common sample processing capability. Through
communication connections among the automation system, analyzers, and the
laboratory information system (LIS) or middleware, the automation software
provides workload and sample-order management, as well as instrument operational
status monitoring.

For complete information, see the product information at

About Abbott Diagnostics

Abbott is a global leader in  in vitro  diagnostics and offers a broad range of
innovative instrument systems and tests for hospitals, reference labs, molecular
labs, blood banks, physician offices and clinics. With more than 22,000
customers in more than 100 countries, Abbott's diagnostic products offer
customers automation, convenience, bedside testing, cost-effectiveness, and
flexibility. Abbott has helped transform the practice of medical diagnosis from
an art to a science through the company's commitment to improving patient care
and lowering costs.

About Abbott

Abbott is a global healthcare company devoted to improving life through the
development of products and technologies that span the breadth of healthcare.
With a portfolio of leading, science-based offerings in diagnostics, medical
devices, nutritionals and branded generic pharmaceuticals, Abbott serves people
in more than 150 countries and employs approximately 70,000 people.  

Visit Abbott at  and connect with us on Twitter at @AbbottNews.

1 Rajkovich, D, Mercer, W. The Impact of Automation on Laboratory Operations. 
CHI Solutions  2009; 1-3.

2  Diagnostics and Policy: Innovation and Value. Accessed  March
7, 2013.

SOURCE  Abbott

Media, Darcy Ross, (847) 937-3655, or Jessica Masuga, (847) 935-0650; or
Financial, Tina Ventura, (847) 935-9390

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.